Intercept Pharmaceuticals Inc. (ICPT) Earns Outperform Rating from Wedbush
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)‘s stock had its “outperform” rating reaffirmed by analysts at Wedbush in a research report issued on Saturday. They presently have a $224.00 price target on the biopharmaceutical company’s stock. Wedbush’s target price indicates a potential upside of 93.37% from the company’s current price.
Several other brokerages have also issued reports on ICPT. Wells Fargo & Co. reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 28th. Robert W. Baird reissued an “outperform” rating and issued a $332.00 target price on shares of Intercept Pharmaceuticals in a research report on Thursday, September 22nd. Credit Suisse Group AG reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Thursday, September 22nd. JMP Securities restated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Thursday, August 18th. Finally, FBR & Co restated a “market perform” rating and issued a $200.00 price target on shares of Intercept Pharmaceuticals in a research note on Thursday, August 18th. Five investment analysts have rated the stock with a sell rating, four have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Intercept Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $177.07.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 1.37% during mid-day trading on Friday, reaching $115.84. The company had a trading volume of 207,545 shares. The company has a 50 day moving average price of $124.14 and a 200 day moving average price of $145.79. The company’s market capitalization is $2.87 billion. Intercept Pharmaceuticals has a one year low of $89.76 and a one year high of $186.87.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($3.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.82) by $0.23. Intercept Pharmaceuticals had a negative return on equity of 66.97% and a negative net margin of 3,287.95%. The firm earned $4.70 million during the quarter, compared to analyst estimates of $4.77 million. During the same quarter in the prior year, the company earned ($2.10) EPS. The business’s revenue was up 1051.1% compared to the same quarter last year. On average, analysts anticipate that Intercept Pharmaceuticals will post ($15.63) EPS for the current year.
In other Intercept Pharmaceuticals news, CMO David Shapiro sold 3,545 shares of the firm’s stock in a transaction dated Monday, September 26th. The stock was sold at an average price of $165.08, for a total transaction of $585,208.60. Following the sale, the chief marketing officer now directly owns 45,732 shares of the company’s stock, valued at $7,549,438.56. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Mark Pruzanski sold 35,000 shares of the firm’s stock in a transaction dated Tuesday, September 20th. The shares were sold at an average price of $165.00, for a total value of $5,775,000.00. Following the sale, the chief executive officer now directly owns 579,314 shares in the company, valued at $95,586,810. The disclosure for this sale can be found here. Company insiders own 9.20% of the company’s stock.
A number of large investors have recently bought and sold shares of the stock. CENTRAL TRUST Co acquired a new stake in Intercept Pharmaceuticals during the second quarter worth approximately $107,000. The Manufacturers Life Insurance Company acquired a new stake in Intercept Pharmaceuticals during the third quarter worth approximately $114,000. KBC Group NV boosted its stake in Intercept Pharmaceuticals by 660.2% in the third quarter. KBC Group NV now owns 897 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 779 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Intercept Pharmaceuticals by 67.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 915 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 370 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in Intercept Pharmaceuticals by 4.5% in the second quarter. Legal & General Group Plc now owns 1,196 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 52 shares in the last quarter. 81.54% of the stock is currently owned by institutional investors and hedge funds.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.